Recipient treatment with acetylcholinesterase inhibitor donepezil attenuates primary graft failure in rats through inhibiting post-transplantational donor heart ischaemia/reperfusion injury. Eur J Cardiothorac Surg 2018;53:400-8.
INTRODUCTION
The pathogenesis of graft failure involves both immune rejection and inflammation. Even without visible signs of immune rejection, transplanted donor heart may be affected by sustained ischaemia/reperfusion and ensuing systemic inflammation in the long term [1] . Protection of the donor heart is vital for successful cardiac transplantation [2] . Although research has focused on improvement of cardioplegia formulae, few interventions are targeting the pathophysiological status of the host.
Previous studies demonstrated that vagus nerve stimulation is cardioprotective [3, 4] . The mechanisms that were originally thought to be dependent on antisympathetic effects were revealed to be actually mutifactorial. Nevertheless, the unique effects of vagus nerve stimulation are quite important for cardioprotection. Borovikova et al. [5, 6] found a parasympathetic anti-inflammatory pathway that is abolished by antagonism against a7 nicotinic acetylcholine receptor (a7-nAChR), the only homomeric nAChR receptor that is widely †The first two authors contributed equally to this study. distributed in the mammalian central nervous system. Through this pathway, the main vagus nerve neurotransmitter, acetylcholine (ACh), significantly inhibits the release of cytokines that mediate ischaemia/reperfusion injury [6] [7] [8] [9] .
However, vagal stimulation could not act on denervated cardiac grafts. In addition, this manoeuvre is invasive and requires special devices that reduce feasibility in clinical application. Donepezil (DO) is a long-acting, reversible acetylcholinesterase inhibitor that is used for the treatment of Alzheimer's disease. It was shown that DO increases the level of vagal neurotransmitter by inhibiting enzymatic breakdown of ACh, enhancing activation of the cholinergic receptor [10] . Taken together, we hypothesize that DO may protect transplanted donor heart by increasing ACh level, which in turn inhibits systemic inflammation in the transplant recipients. To exclude the effects of immune rejections and the need to use immunosuppressors such as cyclosporine, we chose a syngeneic experimental model of Lewis-to-Lewis heart transplantation.
This study was designed to investigate whether DO is able to protect the donor heart in the long term by attenuating inflammation in the recipients using a murine heart transplantation model.
MATERIALS AND METHODS

Animals and experimental design
All animal experimental procedures were performed in compliance with the guidelines in the Regulation to the Care and Use of Experimental Animal (1996) of the Beijing Council on Animal Care and were approved by the Ethics Committee for Animal Study of Fuwai Hospital. Eight-week-old inbred syngeneic male Lewis rats weighing 250-300 g were maintained in laminar flow cages in a pathogen-free animal facility at the affiliated Animal Experimental Center of Fuwai Hospital. Overall experimental design is shown in Supplementary Material, Fig. 1 . In general, a total of 75 recipient rats were randomly assigned into 3 groups using computergenerated random numbers after successful establishment of the transplantation model: the donepezil group (DO group, n = 25), the donepezil + methyllycaconitine group (DO + MLA group, n = 25) and the control group (n = 25).
Animals were euthanized, and transplanted hearts were harvested for terminal deoxynucleotidyl transferase-mediated 2 0 -deoxyuridine 5 0 -biotin nick-end labelling (TUNEL) assay, and serum proinflammatory cytokines [tumour necrosis factor a (TNF-a)-, interleukin (IL)-1b and IL-6] were detected by enzymelinked immunosorbent assay, western blotting and immunofluorescence at 24 h after transplantation. Additional blood samples were used for detection of postoperative serum TNF-a level from Day 1 to Day 7 and at 2-week and 1-month time points. Focal myocardial fibrosis was examined by collagen Masson's trichrome staining at 1 month after surgery. Donor heart functions were examined at 1 month by transthoracic echocardiography (TTE). Survivals of the cardiac grafts in the 3 experimental groups were compared over a 1-month period.
Drug administration
DO (Sigma Aldrich Co., St Louis, MO, USA) was intragastrically administered to the recipients in a single dose (5 mg/kg) 1 h after transplantation and daily at the same dose thereafter.
We chose methyllycaconitine (MLA), an alkaloid isolated from Delphinium brownii, to inhibit a7-nAChR activity. MLA was reported to be the most potent non-protein competitive antagonist of a7-nAChR currently available and was mainly used for experimental purposes [9] . For DO antagonizing experiments, 3 mg/kg/ day MLA (Instrumentation Laboratory Co., Bedford, MA, USA) was administered intraperitoneally 30 min before DO administration. For animals in the DO group and the control group, saline only was injected intraperitoneally.
Rat model of cardiac transplantation
Heterotopic cardiac transplantation was performed. Donor rats were first heparinized (1000 U intraperitoneally) and anaesthetized with 2% Pentobarbital (0.2 ml/100 g). An abdominal incision was made and extended to the thoracic cavity, and then the chest wall was removed. Next, blunt dissection of the heart, aorta and pulmonary artery was performed. The pulmonary veins and inferior vena cava were ligated, and the graft was excised. We routinely preserved cardiac grafts using iced saline as described in the literature [11] . Because the current study focused on recipients' pathophysiological status, we did not attempt to adopt additional cardiac protection strategies during the ischaemic period. Recipient rats were then anaesthetized with 2% Pentobarbital (0.2 ml/100 g). A mid-line laparotomy was performed. The abdominal aorta and vena cava were dissected and clamped with straight vascular clamps to prevent bleeding. A longitudinal aortotomy and venotomy of about 5 mm in length was performed. Using standard microvascular suturing techniques with 8-0 Prolene suture, end-to-side anastomoses were made between aorta and the abdominal aorta and between the pulmonary artery and the inferior vena cava. Haemostasis was achieved, and the incision was closed with a 3-0 silk running suture. Graft survival was evaluated by daily palpation. Cessation of heart beat will prompt ultrasound to confirm death of grafts.
Evaluation of the cardiac function
Cardiac function was examined by 2D echocardiography on sedate animals before drug administration (n = 15 in each group) and at 1 month (DO group: n = 12; DO + MLA group: n = 4; control group: n = 5). All measurements were performed 3 times in a blind fashion and were averaged for statistical analysis. With an HP Sonos 7500 Imaging System, echocardiographic assessment was performed using a 12.5-MHz linear-array probe specifically designed for cardiac ultrasonic studies in small animal models [12] . Left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVESD) were measured from the short-axis view of the left ventricle at the level of papillary muscle. Fractional shortening (FS) was calculated as FS (%) = [(EDD -ESD)/EDD] Â 100.
Proinflammatory cytokines and markers of myocardial injury
Blood samples were drawn from the rat tail vein, incubated overnight at 4 C and centrifuged at 3000 rpm for 15 min. Serum was separated for measurement of proinflammatory cytokines (TNFa, IL-1b and IL-6) and markers of myocardial injury (n = 10 in each group). In all the 3 groups, creatine kinase-MB (CK-MB) was determined using a commercial CK-MB assay kit (Roche Diagnostics, Mannheim, Germany) on an automatic biochemistry analyser (Hitachi 7600, Tokyo, Japan). The Cardiac Troponin I (cTnI) levels were also assayed by commercial kits (Bayer Corp., Tarrytown, NY, USA) on an ACS:180 automated chemiluminescence system (Bayer Corp.).
Protein markers for inflammatory cell infiltration, apoptosis and fibrosis
Western blot analysis (n = 5 in each group) was performed to detect the in situ expression of E-select in (catalogue no. ab6630, Abcam), intercellular cell adhesion molecule 1 (catalogue no. ab2213, Abcam), vascular cell adhesion molecule 1 (catalogue no. ab134047, Abcam), cysteinyl aspartate-specific proteinase 3 (Caspase 3; catalogue no. ab32351, Abcam), cysteinyl aspartatespecific proteinase 8 (Caspase 8; catalogue no. ab25901, Abcam), transforming growth factor b1 (TGF-b1; catalogue no. ab64715, Abcam) and SMAD 2 (catalogue no. ab188334, Abcam). Myocardial tissues were obtained from cardiac grafts at 24 h after DO treatment. Tissue lysates were separated on sodium dodecyl sulphate polyacrylamide gel electrophoresis, followed by standard western blot analysis procedures with a-actin as the internal standard. Horseradish peroxidase-linked secondary antibodies (Zhongshan Gold Bridge Biology Company, Beijing, China) were used, and proteins were visualized by enhanced chemiluminescence on radiography films. Densitometric quantification was performed using the Total Lab image analysis software (Total Laboratory Systems Ltd).
CD11b/18 cell infiltration
At 24 h, animals were euthanized, and hearts were removed for CD11b/18 staining (n = 5 in each group). Cardiac graft tissues were fixed in standard formalin and embedded in paraffin for immunofluorescence staining. Slides from 5 rats from each group were prepared as previously described [12] . Generally, slides were dried at 68 C for 45 min and paraffin was removed step by step, and then slides were placed in heated sodium citrate buffer for 2 min. Slides were incubated with 5% normal goat serum (ZSGB-BIO, Beijing, China) in phosphate-buffered saline for 1 h at room temperature and incubated with primary antibody overnight at 4 C. Next day, slides were warmed up at 37 C for 45 min and then incubated with Alexa Fluro594 conjugated secondary antibody at 37 C in dark, mounted with fluorescent mounting medium and observed under a confocal scanning laser microscope (Sp8; Leica, Germany). Additional sections were obtained for staining by Masson's trichrome.
Slides were stained with anti-CD11b/18 antibody (1:150; ab13219, Abcam) to detect CD11b/18 expression. Secondary antibody used in this study was fluorescein (Alexa Fluro594)-conjugated AffiniPure goat antimouse immunoglobulin G (H + L) (1:500; Proteintech). Nuclei were counterstained with 0.1% 4 0 ,6-diamidino-2-phenylindole (DAPI; ZSGB-BIO). Sections were also obtained from transplanted hearts at 1 month following the procedure and stained by Masson's trichrome (n = 12 in DO group; n = 5 in control group; n = 4 in DO + MLA group). To calculate the rate of positive staining, 5 fields were randomly selected from each section. The percentage of positively staining cells per field was calculated from counting by 2 investigators blinded to the study and were averaged for statistical analysis.
Density of Aniline blue-stained collagen was determined under 40Â magnification of a light microscope (Olympus BX61). Five fields were randomly selected, and the Aniline blue-staining density was expressed as the collagen volume fraction (area of collagen/area of the selected field, %).
Apoptosis assay
TUNEL assay and DAPI double staining (n = 5 in each group) were employed. Cardiomyocyte apoptosis was assessed by the TUNEL assay. Briefly, apoptotic cells were identified using an in situ cell death detection kit (Roche) following the manufacturer's instructions, and total nuclei were counter stained with 4 0 ,6-diamidino-2-phenylindole (DAPI). For each group, 20 randomly selected fields (5 hearts per group, 5 fields per heart) were observed. Apoptotic index, i.e. the percentage of apoptotic nuclei (green TUNEL positive) to the total number of nuclei (blue DAPI positive), was determined.
Statistical methods
Data were expressed as means ± SEM and frequencies (expressed as percentage). Statistical analyses were performed using SPSS 18.0 software (SPSS, Inc., Chicago, IL, USA).
For cross-sectional analyses (IL-1b, IL-6, CK-MB and cTnI; protein indices for inflammatory cell infiltration, apoptosis and fibrosis; CD11b/18 cell infiltration and apoptosis assay), differences among the 3 groups were tested by one-way analysis of variance (ANOVA) with Bonferroni correction. Differences in serum TNF at each time points in each group were examined by one-way ANOVA with repeated measures, with the treatment allocation as a between-subjects factor, the time as a within-subjects factor and time by treatment as interaction. Mauchly's test indicated a P-value of 0.010, suggesting violation of assumption of sphericity. Therefore, 3 additional corrections (Greenhouse-Geisser, HuynhFeldt and low bound) were further conducted [13] . Differences in TTE findings before and during treatment were examined by analysis of co-variance. Survival data were presented as the KaplanMeier curves. A P-value of <0.05 was considered significant.
RESULTS
The average ischaemic time was 34.4 ± 4.7 min; there were of no significant differences among the 3 groups (DO vs DO + MLA: 33.4 ± 4. 
Experimental parameters at 24 h after the first drug administration
Serum level of proinflammatory cytokines and indices for myocardial injury. Because homogeneity cannot be assumed (Mauchly's sphericity test: P = 0.010), we conducted corrections in the repeated-measures ANOVA for TNF. As shown in Fig. 1A , the difference in the TNF levels over time was statistically significant (Greenhouse-Geisser: P < 0.001; Huynh-Feldt: P < 0.001; low bound: P < 0.001), and the treatment by time interaction was of no statistical significance (Greenhouse-Geisser: P = 0.117; HuynhFeldt: P = 0.109; low bound: P = 0.131). The TNF levels among the 3 groups were significantly different (P < 0.001; post hoc analysis: DO vs DO + MLA: P = 0.001; DO vs control: P < 0.001; DO + MLA vs control: P = 0.89). As shown in Fig. 1B , other proinflammatory cytokines, IL-1b and IL-6, were also significantly lower in the DO group when compared with the other 2 groups (for IL-1b, DO vs DO + MLA: P = 0.015, DO vs control: P = 0.04, DO + MLA vs control: P = 0.65; for IL-6, DO vs DO + MLA: P = 0.006, DO vs control: P = 0.017, DO + MLA vs control: P = 0.64). Figure 1C shows that myocardial injury indices were significantly lower in the DO group when compared with the other 2 groups (for cTnI, DO vs DO + MLA: P < 0.001, DO vs control: P < 0.001, DO + MLA vs control: P = 0.53; for CK-MB, DO vs DO + MLA: P = 0.022, DO vs control: P = 0.031, DO + MLA vs control: P = 0.88).
Infiltration of CD 11b/18-positive cells and other related markers. Significantly less CD11b/18-positive cell infiltration was found in the DO group in comparison with the DO + MLA and the control groups (P < 0.001; post hoc analysis: DO vs DO + MLA: P < 0.001; DO vs control: P < 0.001; DO + MLA vs control: P = 0.14, Fig. 2) . Similarly, the expression of E-selectin, intercellular cell adhesion molecule and vascular cell adhesion molecule were significantly lower in the DO group than in the other 2 groups (Fig. 2 , for E-selectin, P = 0.035; for intercellular cell adhesion molecule, P = 0.041; for vascular cell adhesion molecule, P = 0.009).
Cell apoptosis. The percentage of TUNEL-positive nuclei was significantly lower in the DO group than the DO + MLA and the control group (Fig. 3 , P = 0.039; post hoc analysis: DO vs DO + MLA: P = 0.024; DO vs control: P = 0.028; DO + MLA vs control: P = 0.94). The levels of Caspase 8 and Caspase 3 were significantly lower in the DO group when compared with the other 2 groups (Fig. 3 , for Caspase 8, P = 0.031; for Caspase 3, P = 0.027).
Transforming growth factor b1 and SMAD 2. As shown in Fig. 4 , the collagen volume fraction as an indicator of fibrosis was lower in the DO group than in the other 2 groups (P < 0.001; post hoc analysis: DO vs DO + MLA: P < 0.001; DO vs control: P < 0.001; DO + MLA vs control: P = 0.052). Furthermore, expression of TGFb1 and SMAD 2 was significantly lower in the DO group than that in the DO + MLA group and the control group (for TGF-b1, ANOVA P = 0.038; for SMAD 2, ANOVA P = 0.048).
Long-term experimental parameters
Survival analysis. The ratio of cardiac grafts that survived for the 1-month experimental period was significantly higher in rats given DO alone (80.0%; n = 12) than those in the DO + MLA group (26.7%; n = 4) and the control group (33.3%; n = 5; P = 0.014; Fig. 5 ).
Cardiac function by transthoracic echocardiography at 1 month after transplantation. 34.09 ± 0.37%, control: 33.94 ± 0.31%; P = 0.60) were not significantly different among the 3 groups. As presented in Table 1 , LVESD and LVEDD at 1 month were significantly increased in the DO + MLA group and the control group (LVESD: P < 0.001; post hoc analysis: DO vs DO + MLA: P < 0.001; DO vs control: P < 0.001; DO + MLA vs control: P = 0.060; LVEDD: P < 0.001; post hoc analysis: DO vs DO + MLA: P < 0.001; DO vs control: P < 0.001; DO + MLA vs control: P = 0.78). FS was 29.25% in the DO group, which were 17.92% and 17.07% in the DO + MLA and the control group, respectively (P < 0.001; post hoc analysis: DO vs DO + MLA: P < 0.001; DO vs control: P < 0.001; DO + MLA vs control: P = 0.64). Data for TTE video at the 1-month time point are provided in Supplementary Material online.
Focal fibrosis of the cardiac graft. Percentage of collagen area to total tissue was significantly lower in the DO group than that in the DO + MLA and the control group (Fig. 4) .
DISCUSSION
The supply-demand imbalance of donor hearts is a great challenge for the clinical practice of heart transplantation [14] . Graft failure does not only cause disastrous consequences for patients but also accounts for serious waste of medical resources. Therefore, donor heart protection is one of the core issues for successful heart transplantation. This study attempted to modulate the inflammatory state of the recipients with DO treatment, and our results showed that single-dose intragastric DO administration improved the survival rate and post-transplantational function of the cardiac graft.
Although clinical immunosuppressive strategies such as administration of cyclosporine and cortisone showed effective control of acute immune rejection, chronic cardiac graft failure is still a major concern for the long-term survival of the recipients [15] . Various strategies focusing on immune suppression have been were proposed to improve the prognosis of heart transplantation. Fukahori et al. [16] demonstrated that selective inhibition of protein kinase Ch, a measurement that specifically suppresses T cell, significantly reduced the rate of acute rejection and improved graft survival in a rat model. This study and others showed promising safety and efficacy of immunosuppressive strategies to prolong graft survival [17, 18] .
However, it is known that graft failure involves both immune rejection and inflammation. In a 1-year biopsy follow-up study of patients who received heart transplantation, Goland et al. [1] reported that a significant increase in myocardial fibrosis was seen without evidence of rejection, indicating a chronic inflammatory process in graft failure.
Khanna et al. [11] also found that a prolonged inflammatory state in recipients caused graft failure in a murine model. Besides graft rejection due to immune responses of the recipients, chronic allograft vasculopathy is a long-term sequelae of cardiac transplantation, which is characterized by intimal thickening due to extracellular matrix accumulation, inflammatory cell infiltration and smooth muscle cell proliferation [19] .
Previous human studies demonstrated that cardiac graft remodelling was parallel to myocardial overexpression of TNF-a [20] . Actually, as an important proinflammatory factor, TNF plays a key role in ischaemia/reperfusion injuries and triggers multiple inflammatory reactions on a variety of receptor-bearing target cells [8, 21] . However, although anti-TNF therapy was attempted in transplantation of other solid organs [22] , it was never adopted in cardiac transplantation.
Vagal stimulation attenuates systemic inflammation through inhibiting the release of macrophage TNF-a [7] . Further study indicated that a7-nAChR was required for ACh inhibition of TNFa release from macrophages [6] . The a7-nAChR is widely distributed in mammalian central nervous system and involves in many important brain functions, such as cognition, vestibular function and possibly smoking cessation [23] .
Previous studies demonstrated myocardial protective effects of vagal nerve stimulation [3, 4] . However, vagal stimulation cannot directly act on denervated cardiac grafts, so alternative protective treatment is needed for cardiac graft in clinical practice. DO is a long-acting reversible acetylcholinesterase, which leads to increased function of ACh. Li et al. [24] demonstrated that oral DO markedly improved the long-term survival of rats with chronic heart failure. Nevertheless, although the authors observed lowered levels of catecholamine and tissue proinflammatory markers, the underlying mechanisms were not further sought.
Our results showed that recipient treatment with DO can achieve long-term protection of the cardiac graft: the survival rate in the DO group was 46.7% and 53.3% higher than that in the control group and the DO + MLA group, respectively (P = 0.014); the FS value in the DO group was 12% and 11% higher than that in the control group and the DO + MLA group, respectively (P < 0.05).
We also demonstrated that DO administration blunted several downstream pathways of TNF-a that are known to be involved in cardiac remodelling and progress of heart failure: (i) reducing CD11b/18 + cell infiltration; (ii) inhibiting myocardial apoptosis and (iii) reducing myocardial fibrosis by inhibiting the TGF-b pathway. Furthermore, the cardiac graft protective effects of DO were inhibited by MLA administration, suggesting that the a7-nAChR pathway was involved in DO-mediated cardiac graft protection.
Limitations
Several weaknesses of this study are noted here. First, the heart transplantation model we adopted was an unloaded ventricular model. Therefore, cardiac function evaluated by echocardiography should be cautiously interpreted and may not be readily translated into clinical settings.
Second, similar to other types of anti-TNF therapies, DO downregulates TNF-a level at large, an action that inhibits both the harmful and the beneficial functions of TNF-a [25] . In addition, studies in the past decade suggest that anti-TNF therapy increases the risk of infection due to the important regulatory role of TNF in the immune system. Long-term inhibition of TNF may also lead to autoimmune diseases such as systemic lupus erythematosus, type I diabetes mellitus, vasculitis, multiple sclerosis and psoriasis [26] [27] [28] [29] .
Although unlikely, these abovementioned detrimental consequences of the DO therapy must be taken into consideration when translating the findings of the current study into clinical use. In addition, other aspects for consideration are the length of the DO therapy, because long-term anti-TNF treatment in heart transplantation is a safety concern. In a randomized controlled meta-analysis trials on rare adverse effects of anti-TNF therapy, Bongartz et al. [30] demonstrated that in patients treated with anti-TNF antibodies, the number needed to harm was 154 (95% confidence interval 91-500) for developing 1 additional malignancy within 6-12 months of treatment period; and the number needed to harm was 59 (95% confidence interval 39-125) for developing serious infections within 3-12 months of treatment period. The optimal medication duration needs to be carefully assessed in possible future clinical trials.
Moreover, DO treatment carries the risks to elicit adverse events in many organs including adverse cardiovascular events. Therefore, the benefits of DO for cardiac graft should be carefully weighed against its possible risks. The protective effects of DO found in the current study also need to be further confirmed in future studies including clinical trials.
Third, instead of calculating sample size, we decided on sample size according to previous similar studies [11] . However, we used rats of same strain with similar body weight and age as well as the same gender. Finally, weighing between the robustness of the study and laboratory capacity was another factor prompting us to abandon sample size calculation.
CONCLUSION
This study found that in a rat model of syngeneic heterotopic heart transplantation, single-dose intragastric DO can increase survival rate and improve function of the transplanted donor heart for 1 month. This protective role is related to AChmediated inhibition of systemic inflammation and TNF-a-related pathophysiological downstream pathways. This study suggested a novel and feasible clinical measure for donor heart protection focusing on controlling pathophysiological state of the recipients.
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